Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

In a report released yesterday, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with ...

In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against other best performing healthcare stocks so far in 2025. Despite the ongoing craze ...

The New York-based company said it had a loss of $1.54 per share. Losses, adjusted for non-recurring costs, were 96 cents per share. The results topped Wall Street expectations.

Below is Validea's guru fundamental report for AXSOME THERAPEUTICS INC (AXSM). Of the 22 guru strategies we follow, AXSM rates highest using our Value Investor model based on the published ...